| Autor: |
Kennedy, Sidney H., Lam, Raymond W., Cohen, Nicole L., Rosenbluth, Michael, Sokolov, Stephen T.H., McIntyre, Roger S., Chue, Pierre, Craigen, Gerry |
| Předmět: |
|
| Zdroj: |
Journal of Psychiatry & Neuroscience; Nov2002, Vol. 27 Issue 6, p418, 5p |
| Abstrakt: |
Objective: To describe the effectiveness and tolerability of reboxetine under Special Access Program conditions in Canada in a group of patients with refractory depressive disorders. Design: Retrospective open-label study. Setting: Six clinical academic settings in Canada, primarily tertiary institutional settings. Patients: Twenty-six female and 19 male outpatients with depressive disorders, primarily unipolar depression. Most of the patients were treatment resistant. Intervention: Reboxetine through the Special Access Program. Outcome measure: Severity of depression before treatment with reboxetine was retrospectively assessed with the Clinical Global Impression (CGI) Global Severity Scale; change with treatment was evaluated with the CGI Global Improvement Scale. Results: Before reboxetine treatment, 20 (44%) patients scored in the moderate CGI severity category, II (24%) in the marked category and 12 (27%) in the severe category. The dose range for reboxetine was 2-16 mg, with 40 (89%) patients in the 4-10 mg range. With reboxetine treatment, 25 (56%) patients were considered "very much improved" or "much improved"; 8 (18%) patients were "minimally improved"; 7 (16%) received ratings that reflected "no change" or minimal worsening, and 5 (11%) were rated as "much worse" or "very much worse." Conclusions: Reboxetine was effective at a clinically meaningful level in decreasing severity of depression in 56% of patients. Given the high rate of prior resistance to other antidepressant therapies, there is a definite role for this agent in the treatment of depressive disorders. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
